Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00103428 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: CG7870

Sponsor

Cell Genesys